Antioxidant activity of galantamine and some of its derivatives

Current Medicinal Chemistry

Volumn 20, Issue 36, 2013, Pages 4595-4608

  Tsvetkova, D ^a   Obreshkova, D ^a   Zheleva Dimitrova, D ^a   Saso, L ^b  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antioxidant activity; Derivatives; Galantamine; Neurodegeneration; Oxidative stress

Indexed keywords

ALCOHOL; AMYLOID BETA PROTEIN[1-42]; CURCUMIN; DEMETHOXYCURCUMIN; GALANTAMINE; GLUCOSE; GLUTAMIC ACID; OXYGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN SERINE THREONINE KINASE; SILIBININ; SILICRISTIN; SILIDIANIN;

AGING; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CELL VIABILITY; CEREBRAL PALSY; CEREBROVASCULAR DISEASE; CURCUMA LONGA; CYTOTOXICITY; DEFENSE MECHANISM; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME PHOSPHORYLATION; GALANTHUS; GINKGO BILOBA; HUMAN; MELISSA OFFICINALIS; MEMBRANE FLUIDITY; MITOCHONDRIAL MEMBRANE POTENTIAL; MULTIINFARCT DEMENTIA; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYOTONIC DYSTROPHY; NARCISSUS; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; POLIOMYELITIS; POLYNEUROPATHY; POLYRADICULONEUROPATHY; PROGRESSIVE MUSCULAR DYSTROPHY; PROTEIN EXPRESSION; SALVIA OFFICINALIS; SCHIZOPHRENIA; THOMSEN DISEASE; TOBACCO DEPENDENCE; TRIBULUS TERRESTRIS; WERDNIG HOFFMANN DISEASE;

ANIMALS; ANTIOXIDANTS; GALANTAMINE; HUMANS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84887917706     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990148     Document Type: Article

References (142)

1. Butterfield, D.A.; Howard, B.J.; LaFontaine, M.A. Brain oxidative stress in animal models of accelerated aging and the age-related neurodegenerative disorders, Alzheimer's disease and Huntington's disease. Curr. Med. Chem., 2001, 8(7), 815-828.
2. Dalle-Donne, I.; Rossi, R.; Colombo, R.; Giustarini, D.; Milzani, A. Biomarkers of oxidative damage in human disease. Clin. Chem., 2006, 52(4), 601-623.
3. Barnham, K.J.; Masters, C.L.; Bush, A.I. Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov., 2004, 3(3), 205-214.
4. Halliwell, B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging, 2001, 18(9), 685-716.
5. Smith, M.A.; Rottkamp, C.A.; Nunomura, A.; Raina, A.K.; Perry, G. Oxidative stress in Alzheimer's disease. Biochim. Biophys. Acta Mol. Basis Dis., 2000, 1502(1), 139-144.
6. Butterfield, D.A. Amyloid ß-peptide [1-42]-associated free radicalinduced oxidative stress and neurodegeneration in Alzheimer's disease brain: mechanisms and consequences. Curr. Med. Chem., 2003, 10(24), 2651-2659.
7. Markesbery, W.R. The role of oxidative stress in Alzheimer disease. Arch. Neurol., 1999, 56(12), 1449-1452.
8. Zalba, G.; Fortuño, A,; Díez, J. Oxidative stress and atherosclerosis in early chronic kidney disease. Nephrol. Dial. Transplant., 2006, 21(10), 2686-2690.
9. Heistad, D.D. Oxidative stress and vascular disease: 2005 Duff Lecture. Arterioscler. Thromb. Vasc. Biol., 2006, 26(4), 689-695.
10. Quintero, M.; Brennan, P.A.; Thomas, G.J.; Moncada, S. Nitric oxide is a factor in the stabilization of hypoxia-inducible factor-1 alpha in cancer: role of free radical formation. Cancer Res., 2006, 66(2), 770-774.
11. Maiese, K.; Morhan, S.D.; Chong, Z.Z. Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr. Neurovasc. Res., 2007, 4(1), 63-71.
12. Wiktorowska-Owczarek, A.; Nowak, J.Z. Pathogenesis and prophylaxis of AMD: focus on oxidative stress and antioxidants. Postepy Hig. Med. Dosw., 2010, 64, 333-343.
13. Firuzi, O.; Spadaro, A.; Spadaro, C.; Riccieri, V.; Petrucci, R.; Marrosu, G.; Saso, L. Protein oxidation markers in the serum and synovial fluid of psoriatic arthritis patients. J. Clin. Lab. Anal., 2008, 22(3), 210-215.
14. Knobloch, M.; Mansuy, I.M. Dendritic spine loss and synaptic alterations in Alzheimer's disease. Mol. Neurobiol., 2008, 37(1), 73-82.
15. Forero, D.A.; Casadesus, G.; Perry, G.; Arboleda, H. Synaptic dysfunction and oxidative stress in Alzheimer's disease: Emerging mechanisms. J. Cell. Mol. Med., 2006, 10(3), 796-805.
16. Schmitt, K.; Strosznajder; J.B.; Götz, J.; Grimm, A.; Kazmierczak, A.; Eckert, A. Insights into mitochondrial dysfunction: aging, amyloid-and tau-A deleterious trio. Antioxidants and Redox Signaling., 2012, 16(12), 1456-1466.
17. Tuppo, E.E; Arias, H.R. The role of inflammation in Alzheimer's disease. Int. J. Biochem. Cell. Biol., 2005, 37(2), 289-305.
18. Moreira, P.I.; Siedlak, S.L.; Aliev, G.; Zhu, X.; Cash, A.D.; Smith, M.A.; Perry, G. Oxidative stress mechanisms and potential therapeutics in Alzheimer disease. J. Neural. Transm., 2005, 112(7), 921-932.
19. Agostinho, P.; Cunha, R.A.; Oliveira, C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr. Pharm. Des., 2010, 16(25), 2766-2778.
20. Nunomura, A.; Castellani, R.J.; Zhu, X.; Moreira, P.I.; Perry, G.; Smith, M.A. Involvement of oxidative stress in Alzheimer disease. J. Neuropathol. Exp. Neurol., 2006, 65(7), 631-641.
21. Liu, Q.; Xie, F.; Rolston, R.; Moreira, P.I.; Nunomura, A.; Zhu, X.; Smith, M.A.; Perry, G. Prevention and treatment of Alzheimer disease and aging: antioxidants. Mini Rev. Med. Chem., 2007, 7(2), 171-180.
22. Nunomura, A.; Perry, G.; Aliev, G.; Hirai, K.; Takeda, A.; Balraj, E.K.; Jones, P.K.; Ghanbari, H.; Wataya, T.; Shimohama, S.; Chiba, S.; Atwood, C.S.; Petersen, R.B.; Smith, M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol., 2001, 60(8), 759-767.
23. Behl, C.; Moosmann, B. Oxidative nerve cell death in Alzheimer's disease and stroke: antioxidants as neuroprotective compounds. Biol. Chem., 2002, 383(3-4), 521-536.
24. Ansari, M.A.; Scheff, S.W. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J. Neuropathol. Exp. Neurol., 2010, 69(2), 155-167.
25. Marlatt, M.W.; Lucassen, P.J.; Perry, G.; Smith, M.A.; Zhu, X. Alzheimer's disease: cerebrovascular dysfunction, oxidative stress and advanced clinical therapies. J. Alzheimers Dis., 2008, 15(2), 199-210.
26. Petersen, R.B.; Nunomura, A.; Lee, H.G.; Casadesus, G.; Perry, G.; Smith, M.A.; Zhu, X. Signal transduction cascades associated with oxidative stress in Alzheimer's disease. J. Alzheimers Dis., 2007, 11(2), 143-152.
27. Axelsen, P.H.; Komatsu, H.; Murray, I.V.J. Oxidative stress and cell membranes in the pathogenesis of Alzheimer's disease. Physiology, 2011, 26(1), 54-69.
28. Münch, G.; Westcott, B.; Menini, T.; Gugliucci, A. Advanced glycation endproducts and their pathogenic roles in neurological disorders. Amino Acids, 2012, 42(4), 1221-1236.
29. Howes, M.-J. R.; Perry, N.S.L.; Houghton, P.J. Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother. Res., 2003, 17(1), 1-18.
30. Perry, E.K.; Pickering, A.T.; Wang, W.W.; Houghton, P.J.; Perry, N.S. Medicinal plants and Alzheimer's disease: from ethnobotany to phytotherapy. J. Pharm. Pharmacol., 1999, 51(5), 527-534.
31. Youdim, K.A.; Joseph, J.A. A possible emerging role of phytochemicals in improving age-related dysfunction: a multiplicity of effects. Free Radic. Biol. Med., 2001, 30(6), 583-594.
32. Kinghorn, A.D.; Su, B.N.; Jang, D.S.; Chang, L.C.; Lee, D.; Gu, J.Q.; Carcache-Blanco, E.J.; Pawlus, A.D.; Lee, S.K.; Park, E.J.; Cuendet, M.; Gills, J.J.; Bhat, K; Park, H.S.; Mata-Greenwood, E; Song, L.L.; Jang, M.; Pezzuto, J.M. Natural inhibitors of carcinogenesis. Planta Med., 2004, 70(8), 691-705.
33. Sabu, M.C.; Kuttan, R. Antidiabetic activity of medicinal plants and it's relationship with their antioxidant property. J. Ethnopharmacol., 2002, 81(2), 155-160.
34. Repetto, M.G.; Llesuy, S.F. Antioxidant properties of natural compounds used in popular medicine for gastric ulcers. Braz. J. Med. Biol. Res., 2002, 35(5), 523-534.
35. Govindarajan, R.; Vijayakumar, M.; Pushpangadan, P. Antioxidant approach to disease management and the role of Rasayana herbs of Ayurveda. J. Ethnopharmacol., 2005, 99(2), 165-178.
36. Gan, R.-Y.; Kuang, L.; Xu, X.-R.; Zhang, Y.; Xia, E.-Q.; Song, F.-L.; Li, H-B. Screening of natural antioxidants from traditional Chinese medicinal plants associated with treatment of rheumatic disease. Molecules, 2010, 15(9), 5988-5997.
37. Auddy, B.; Ferreira, M.; Blasina, F.; Lafon, L.; Arredondo, F.; Dajas, F.; Tripathi, P.C.; Seal, T.; Mukherjee, B. Screening of antioxidant activity of three Indian medicinal plants traditionally used for the management of neurodegenerative diseases. J. Ethnopharmacol., 2003, 84(2-3), 131-138.
38. Cousins, M.; Adelberg, J.; Chen, F.; Rieck, J. Antioxidant capacity of fresh and dried rhizomes from four clones of turmeric (Curcuma longa L.) grown in vitro. Ind. Crop. Prod., 2007, 25(2), 129-135.
39. Singh, G.; Kapoor, I.P.S.; Singh, P.; de Heluani, C.S.; De Lampasona, M.P.; Catalan, C.A.N. Comparative study of chemical composition and antioxidant activity of fresh and dry rhizomes of turmeric (Curcuma longa). Food Chem. Toxicol., 2010, 48(4), 1026-1031.
40. Jayaprakasha, G.K.; Jaganmohan-Rao, L.J.; Sakariah, K.K. Antioxidant activities of curcumin, demethoxycurcumin and bisdemethoxycurcumin. Food Chem., 2006, 98(4), 720-724.
41. Ak, T.; Gülçin, I. Antioxidant and radical scavenging properties of curcumin. J. Chem.-Biol. Interact., 2008, 174(1), 27-37.
42. Obreshkova, D. Analytical study and quality control of bulgarian drugs with antioxidant activity. Pharmacia, 2012, LVII(1-4), 107-114.
43. Tepe, B.; Sihoglu-Tepe, A.; Daferera, D.; Polissiou, M.; Sokmen, A. Chemical composition and antioxidant activity of the essential oil of Clinopodium vulgare L. Food Chem., 2007, 103(3), 766-770.
44. Nencini, C.; Giorgi, G.; Micheli, L. Protective effect of silymarin on oxidative stress in rat brain. Phytomedicine, 2007, 14(2-3), 1291-1135.
45. Shaker, E.; Mahmoud, H.; Mnaa, S. Silymarin, the antioxidant component and Silybum marianum extracts prevent liver damage. Food Chem. Toxicol., 2010, 48(3), 803-806.
46. Majumdar, A.S.; Saraf, M.N.; Andrades, N.R.; Kamble, R.Y. Preliminary studies on the antioxidant activity of Tribulus terrestris and Eclipta alba. Pharmacognosy Magazine, 2008, 13(4), 102-107.
47. Pandey, R.; Shankar, B.; Sainis, K. Tribulus terrestris fruit extract protects against oxidative stress-induced apoptosis. Pharm. Biol., 2007, 45(8), 619-625.
48. Marco, L.; do Carmo Carreiras, M. Galanthamine, a natural product for the treatment of Alzheimer's disease. Recent Pat. CNS Drug Discov., 2006, 1(1), 105-110.
49. Villaroya, M.; Garcia, A.G.; Marco-Contelles, J.; Lopez, M.G. An update on the pharmacology of galantamine. Expert. Opin. Investig Drugs, 2007, 16(12), 1987-1998.
50. Arias, E.; Alés, E.; Gabilán, N.H.; Cano-Abad, M.F.; Villarroya, M.; García, A.G.; López, M.G. Galantamine prevents apoptosis induced by ß-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacol., 2004, 46(1), 103-114.
51. Wang, D.; Noda, Y.; Zhou, Y.; Mouri, A.; Mizoguchi, H.; Nitta, A.; Chen, W.; Nabeshima, T. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid 25-35 i.c.v.-injected mice: involvement of dopaminergic systems. Neuropsychopharmacol., 2007, 32(6), 1261-1271.
52. Woodruff-Pak, D.S; Vogel, R.W.III; Wenk, G.L. Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc. Natl. Acad. Sci. USA, 2001, 98(4), 2089-2094.
53. Melo, J. B.; Sousa, C.; Garção, P.; Oliveira, C. R.; Agostinho, P. Galantamine protects against oxidative stress induced by amyloidbeta peptide in cortical neurons. Eur. J. Neurosci., 2009, 29(3), 455-464.
54. Ago, Y.; Koda, K.; Takuma, K.; Matsuda, T. Pharmacological aspects of the acetylcholinesterase inhibitor Galantamine. J. Pharmacol. Sci., 2011, 116 (1), 6-17.
55. Takada-Takatori, Y.; Kume, T.; Izumi, Y.; Ohgi, Y.; Niidome, T.; Fujii, T.; Sugimoto, H.; Akaike, A. Roles of nicotinic receptors in acetylcholinesterase inhibitor-induced neuroprotection and nicotinic receptor up-regulation. Biol. Pharm. Bull., 2009, 32(3), 318-324.
56. Takata, K.; Kitamura,Y.; Saeki, M.; Terada, M.; Kagitani, S.; Kitamura, R.; Fujikawa, Y.; Maelicke, A.; Tomimoto, H.; Taniguchi, T.; Shimohama, S. Galantamine-induced amyloid-clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J. Biol. Chem., 2010, 285(51), 40180-40191.
57. Maelicke, A.; Samochocki, M.; Jostock, R.; Fehrenbacher, A.; Ludwig, J.; Albuquerque, E.X.; Zerlin, M. Allosteric sensitization of nicotinicreceptors by galanthamine, a new treatment strategy for Alzheimer's disease. Biol. Psychiatry, 2001, 49(3), 279-288.
58. Samochocki, M.; Höffle, A.; Fehrenbacher, A.; Jostock, R.; Ludwig, J.; Christner, C.; Radina, M.; Zerlin, M.; Ullmer, C.; Pereira, E.F.; Lubbert, H.; Albuquerque, E.X.; Maelicke, A. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors, J. Pharmacol. Exp. Ther., 2003, 305(3), 1024-1036.
59. Matharu, B.; Gibson, G.; Parsons, R.; Huckerby, T.N; Moore, S.A; Cooper, L.J.; Millichamp, R.; Allsop, D.; Austen, B. Galantamine inhibits-amyloid aggregation and cytotoxicity. J. Neurol. Sci., 2009, 280(1-2), 49-58.
60. Geerts, H.; Finkel, L.; Carr, R.; Spitos, A. Nicotinic receptor modulation: advantages for successful Alzheimer's disease therapy. J. Neural. Transm. Suppl., 2002, 62, 203-216.
61. Harvey, A.L. The pharmacology of galanthamine and it's analogues. Pharmacol. Ther., 1995, 68(1), 113-128.
62. Goldstein, D.S.; Holmes, C.; Sato, T.; Bernson, M.; Mizrahi, N.; Imrich, R.; Carmona, G.; Sharabi, Y.; Vortmeyer, A.O. Central dopamine deficiency in pure autonomic failure. Clin. Auton. Res., 2008, 18(2), 58-65.
63. Schilström, B.; Ivanov, V.B.; Wiker, C.; Svensson, T.H. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacol., 2007, 32(1), 43-53.
64. Aronson, S.; Van Baelen, B.; Kavanagh, S.; Schwalen, S. Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post hoc analysis of a randomized, double-blind, placebo-controlled trial. Drugs Aging, 2009, 26(3), 231-239.
65. Bullock, R. Galantamine: use in Alzheimer's disease and related disorders. Exp. Rev. Neurother., 2004, 4(2), 153-163.
66. Lilienfeld, S. Galantamine-a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev., 2002, 8(2), 159-176.
67. Seltzer, B. Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease. Clin. Interv. Aging, 2010, 5, 1-6.
68. Scott, L.J.; Goa, K.L. Galantamine: a review of its use in Alzheimer's disease. Drugs, 2000, 60(5), 1095-1122.
69. Tariot, P. Current status and new developments with galantamine in the treatment of Alzheimer's disease. Expert. Opin. Pharmacother., 2001, 2(12), 2027-2049.
70. Erkinjuntti, T.; Kurz, A.; Gauthier, S.; Bullock, R.; Lilienfeld, S.; Damaraju, C.V. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. Lancet, 2002, 359(9314), 1283-1290.
71. Auchus, A.P.; Brashear, H.R.; Salloway, S.; Korczyn, A.D.; De Deyn, P.P.; Gassmann-Mayer, C. Galantamine treatment of vascular dementia: a randomized trial. Neurology, 2007, 69(5), 448-459.
72. Sobrado, M.; Roda, J.M.; López, M.G.; Egea, J.; García, A.G. Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation. Neurosci. Lett., 2004, 365(2), 132-136.
73. Dengiz, A.N.; Kershaw, P. The clinical efficacy and safety of galantamine in the treatment of Alzheimer's disease. CNS Spectr., 2004, 9(5), 377-392.
74. Raskind, M.A.; Peskind, E.R.; Truyen, L.; Kershaw, P.; Damaraju, C.V. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch. Neurol., 2004, 61(2), 252-256.
75. Pavlov, V.A.; Parrish, W.R.; Rosas-Ballina, M.; Ochani, M.; Puerta, M.; Ochani, K.; Chavan, S.; Al-Abed, Y.; Tracey, K.J. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain Behav. Immun., 2009, 23(1), 41-45.
76. Diehl, A.; Nakovics, H.; Croissant, B.; Smolka, M.N.; Batra, A.; Mann, K. Galantamine reduces smoking in alcohol-dependent patients: a randomized, placebo-controlled trial. Int. J. Clin. Pharmacol. Ther., 2006, 44(12), 614-622.
77. Traykova, M.; Traykov T.; Hadjimitova, V.; Krikorian, K.; Bojadgieva, N. Antioxidant properties of galantamine hydrobromide. Z. Naturforsch. C., 2003, 58(5-6), 361-365.
78. Arias, E.; Gallego-Sandin, S.; Villaroya, M.; Garcia, A.G.; Lopez, M.G. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. J. Pharmacol. Exp. Ther., 2005, 315(3), 1346-1353.
79. Coyle, J.T.; Geerts, H.; Sorra, K.; Amatniek, J. Beyond in vitro data: a review of invivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology. J. Alzheimer Dis., 2007, 11(4), 491-507.
80. Kihara, T.; Shimohama, S.; Sawada, H.; Honda, K.; Nakamizo, T.; Shibasaki, H.; Kume, T; Akaike, A. 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block Aß-induced neurotoxicity. J. Biol. Chem., 2001, 276(17), 13541-13546.
81. Geerts, H. Indicators of neuroprotection with galantamine. Brain Res. Bull., 2005, 64(6), 519-524.
82. Agostinho, P.; Lopes, J.P.; Velez, Z.; Oliveira, C.R. Overactivation of calcineurin induced by amyloid-beta and prion proteins. Neurochem. Int., 2008, 52(6), 1226-1233.
83. Springer, J.E.; Azbill, R.D.; Nottingham, S.A.; Kennedy, S.E. Calcineurin mediated BAD dephosphorylation activates the caspase-3 apoptotic cascade in traumatic spinal cord injury. J. Neurosci., 2000, 20(19), 7246-7251.
84. Li, Q.; Fang, J.; Yang, M.; Wu, D.; Zhang, L.; Zhang, Y. Galantamine inhibits calpain-calcineurin signaling activated by betaamyloid in human neuroblastoma SH-SY5Y cells. Neurosci. Lett., 2010, 480(3), 173-177.
85. Liu, X.; Xu, K.; Yan, M.; Wang, Y.; Zheng, X. Protective effects of galantamine against A-induced PC12 cell apoptosis by preventing mitochondrial dysfunction and endoplasmic reticulum stress. Neurochem. Int., 2010, 57(5), 588-599.
86. Kihara, T.; Sawada, H.; Nakamizo, T.; Kanki, R.; Yamashita, H.; Maelicke, A.; Shimohama, S. Galantamine modulates nicotinic receptor and blocks Aß-enhanced glutamate toxicity. Biochem. Biophys. Res. Commun., 2004, 325(3), 976-982.
87. Takada-Takatori, Y., Kume, T.; Sugimoto, M.; Katsuki, H.; Niidome, T.; Sugimoto, H.; Fujii, T.; Okabe, S.; Akaike, A. Neuroprotective effects of galanthamine and tacrine against glutamate neurotoxicity. Eur. J. Pharmacol., 2006, 549(1-3), 19-26.
88. Takada, Y.; Yonezawa, A.; Kume, T.; Katsuki, H.; Kaneko, S.; Sugimoto, H.; Akaike, A. Nicotinic acetylcholine receptormediated neuroprotection by donepezil against glutamate neurotoxicity in rat corticalneurons. J. Pharmacol. Exp. Ther., 2003, 306(2), 772-777.
89. Pinton, P.; Ferrari, D.; Rapizzi, E.; Di Vigilio, F.; Pozzan, T.; Rizzuto, R. The Ca2+ concentration of the endoplasmic reticulum is a key determinant of ceramide induced apoptosis: significance of the molecular mechanism of Bcl-2 action. Eur. Mol. Biol. Organ. J., 2001, 20(11), 2690-2701.
90. Yanagida, T.; Takeuchi, H.; Kitamura, Y.; Takata, K.; Minamino, H.; Shibaike, T.; Tsushima, J.; Kishimoto, K.; Yasui, H.; Taniguchi, T.; Shimohama, S. Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model. Neurosci. Res., 2008, 62(4), 254-261.
91. Ezoulin, M.J.M.; Ombetta, J.-E.; Dutertre-Catella, H.; Warnet, J.-M.; Massicot, F. Antioxi-dative properties of galantamine on neuronal damage induced by hydrogen peroxide in SK-N-SH cells. Neurotoxicol., 2008, 29(2), 270-277.
92. Nakao; A., Kaczorowski; D.J., Zuckerbraun; B.S., Lei, J.; Faleo, G.; Deguchi, K.; McCurry K.R.; Billiar, T.R.; Kanno, S. Galantamine and carbon monoxide protect brain microvascular endothelial cells by heme oxygenase-1 induction. Biochem. Biophys. Res. Commun., 2008, 367(3), 674-679.
93. Shaw, S.; Bencherif, M.; Marrero, M.B. Janus kinase 2, an early target of alpha 7 nicotinic acetylcholine receptor-mediated neuroprotection against Abeta-(1-42) amyloid. J. Biol. Chem., 2002, 277(47), 44920-44924.
94. Rane, S.G.; Reddy, E.P. Janus kinases: components of multiple signaling pathways. Oncogene, 2000, 19(49), 5662-5679.
95. Madrigal, J.L.; Garcia-Bueno, B.; Caso, J.R.; Perez-Nievas, B.G.; Leza, J.C. Stress induced oxidative changes in brain. CNS Neurol. Disord. Drug Targets, 2006, 5(5), 561-568.
96. Sethi, G.; Sung, B.; Aggarwal, B.B. Nuclear factor-kappaB activation: from bench to bedside. Exp. Biol. Med., 2008, 233(1), 21-31.
97. Egea, J.; Martín-de-Saavedra, M.D.; Parada, E.; Romero, A.; del Barrio, L.; Rosa, A.O.; García, A.G; López, M.G. Galantamine elicits neuroprotection by inhibiting iNOS, NADPH oxidase and ROS in hippocampal slices stressed with anoxia/reoxygenation. Neuropharmacol., 2012, 62(2), 1082-1090.
98. Ji, X.; Li, C.; Lu, Y.; Chen, Y.; Guo, L. Post-ischemic continuous administration of galantamine attenuates cognitive deficits and hippocampal neurons loss after transient global ischemia in gerbils. Neurosci. Lett., 2007, 416(1), 92-95.
99. Lorrio, S.; Sobrado, M.; Arias, E.; Roda, J.M.; García, A.G.; López, M.G. Galantamine postischemia provides neuroprotection and memory recovery against transient global cerebral ischemia in gerbils. J. Pharmacol. Exp. Ther., 2007, 322(2), 591-599.
100. Iliev, A.I.; Traykov, V.B.; Mantchev, G.T.; Stoykov, I.; Prodanov, D.; Yakimova, K.S.; Krushkov, I.M. A post-ischaemic single administration of galanthamine, a cholinesterase inhibitor, improves learning ability in rats. J. Pharm. Pharmacol., 2000, 52(9), 1151-1156.
101. Li, Y.; King, M.A.; Meyer, E.M. Alpha7 nicotinic receptormediated protection against ethanol-induced oxidative stress and cytotoxicity in PC12 cells. Brain Res., 2000, 861(1), 165-167.
102. Capsoni, S.; Giannotta, S.; Cattaneo, A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in antinerve growth factor mice. Proc. Natl. Acad. Sci. USA, 2002, 99(19), 12432-12437.
103. Romero, A.; Egea, J.; García, A.G.; López, M.G. Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH-SY5Y neuroblastoma cells. J. Pineal Res., 2010, 49(2), 141-148.
104. Kumar, A.; Prakash, A.; Pahwa, D. Galantamine potentiates the protective effect of rofecoxib and caffeic acid against intrahippocampal Kainic acid-induced cognitive dysfunction in rat. Brain Res. Bull., 2011, 85(3-4), 158-168.
105. Oh, M.M.; Wu, W.W.; Power, J.M.; Disterhoft, J.F. Galanthamine increases excitability of CA1 hippocampal pyramidal neurons. Neurosci., 2006, 137(1), 113-123.
106. Tayebati, S.K.; Di Tullio, M.A.; Tomassoni, D.; Amenta, F. Neuroprotective effect of treatment with galantamine and choline alphoscerate on brain microanatomy in spontaneously hypertensive rats. J. Neurolog. Sci., 2009, 283(1-2), 187-194.
107. Almasieh, M.; Zhou, Y.; Kelly, M.E.; Casanova, C.; Di Polo, A. Structural and functional neuroprotection in glaucoma: role of galantamine-mediated activation of muscarinic acetylcholine receptors. Cell Death Dis., 2010, 1(2), 27.
108. Barnes, C.A.; Meltzer, J.; Houston, F.; Orr, G.; McGann, K.; Wenk, G.L. Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neurosci., 2000, 99(1), 17-23.
109. Geerts, H.; Guillaumat, P.O.; Grantham, C.; Bode, W.; Anciaux, K.; Sachak, S. Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice and rabbits. Brain Res., 2005, 1033(2), 186-193.
110. Weible, A. P.; Oh, M.M.; Lee, G.; Disterhoft, J.F. Galantamine facilitates acquisition of hippocampus-dependent trace eye blink conditioning in aged rabbits. Learn. Mem., 2004, 11(1), 108-115.
111. De Bruin, N.; Pouzet, B. Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval. Pharmacol. Biochem. Behav., 2006, 85(1), 253-260.
112. Gould, T. J.; Feiro, O.R. Age-related deficits in the retention of memories for cued fear conditioning are reversed by galantamine treatment. Behav. Brain Res., 2005, 165(2), 160-171.
113. Van Dam, D.; De Deyn, P.P. Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model. Eur. Neuropsychopharmacol., 2006, 16(1), 59-69.
114. Woodruff-Pak, D.S.; Vogel, R.W.III; Wenk, G.L. Mecamylamine interactions with galantamine and donepezil: effects on learning, acetylcholinesterase, and nicotinic acetylcholine receptors. Neurosci., 2003, 117(2), 439-447.
115. Hernandez, C.M.; Gearhart, D.A.; Parikh, V.; Hohnadel, E.J.; Davis, L.W.; Middlemore, M.L.; Warsi, S.P.; Waller, J.L.; Terry, A.V., Jr. Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats. J. Pharmacol. Exp. Ther., 2006, 316(2), 679-694.
116. Dimitrova, D.S.; Getova-Spassova, D.P. Effects of galantamine and donepezil on active and passive avoidance tests in rats with induced hypoxia. J. Pharmacol. Sci., 2006, 101(3), 199-204.
117. Traykova, M.; Todorov, L.; Markova, P.; Andreeva, D.; Traykov, T. Effect of Galanthamine on the short memory of spontaneously hypertensive rats (SHR) exposed to insomnia. Trakia J. Sci., 2005, 3(3), 16-19.
118. Iliev, A.; Traykov, V.; Prodanov, D.; Mantchev, G.; Yakimova, K.; Krushkov, I.; Boyadjieva, N. Effect of the acetylcholinesterase inhibitor galanthamine on learning and memory in prolonged alcohol intake rat model of acetylcholine deficit. Methods Find Exp. Clin. Pharmacol., 1999, 21(4), 297-301.
119. Gibbs, R.B.; Chipman, A.M.; Hammond, R.; Nelson. D. Galanthamine plus estradiol treatment enhances cognitive performance in aged ovariectomized rats. Horm. Behav., 2011, 60(5), 607-616.
120. Sweeney, J.E.; Bachman, E.S.; Coyle, J.T. Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice. Psychopharmacol. (Berl), 1990, 102(2), 191-200.
121. Noda, Y.; Mouri, A.; Ando, Y.; Waki, Y.; Yamada, S.-N.; Yoshimi, A.; Yamada, K.; Ozaki, N.; Wang, D.; Nabeshima, T. Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems. Int. J. Neuropsychopharmacol., 2010, 13(10), 1343-1354.
122. Wang, D.; Noda, Y.; Zhou, Y.; Nitta, A.; Furukawa, H.; Nabeshima, T. Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: role of nAChR activationdependent increase of dopamine D1 receptor-mediated neurotransmission. Neuropharmacol., 2007, 53(3), 379-389.
123. Van Dam, D.; Vloeberghs, E.; Abramowski, D.; Staufenbiel, M.; De Deyn, P.P. APP23 mice as a model of Alzheimer's disease: an example of a transgenic approach to modeling a CNS disorder. CNS Spectr., 2005, 10(3), 207-222.
124. Vellas, B.; Cunha, L.; Gertz, H.-J.; De Deyn, P.P.; Wesnes, K.; Hammond, G. Schwalen, S. Early onset effects of Galantamine treatment on attention in patients with Alzheimer's disease. Curr. Med. Res. Opinion, 2005, 21(9), 1423-1429.
125. Galvin, J.E.; Cornblatt, B.; Newhouse, P.; Ancoli-Israel, S.; Wesnes, K.; Williamson, D.; Zhu, Y.; Sorra, K.; Amatniek, J. Effects of galantamine on measures of attention: results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil. Alzheimer Dis. Assoc. Disord., 2008, 22(1), 30-38.
126. Harry, R.D.J.; Zakzanisin, K.K. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis. Hum. Psychopharmacol.: Clin. Exp., 2005, 20(3), 183-187.
127. Erkinjuntti, T.; Kurz, A.; Small, G. W.; Bullock, R.; Lilienfeld, S.; Damaraju, C.V. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin. Ther., 2003, 25(6), 1765-1782.
128. Koontz, J.; Baskys, A. Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study. Amer. J. Alzheimer Dis. Other Demen., 2005, 20(5), 295-302.
129. Pirttilä, T.; Wilcock, G.; Truyen, L.; Damaraju, C.V. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer s disease: multicenter trial. Eur. J. Neurol., 2004, 11(11), 734-741.
130. Bores, G.M.; Huger, F.P.; Petko, W.; Mutlib, A.E.; Camacho, F.; Rush, D.K.; Selk, D.E.; Wolf, V.; Kosley, R.W. Jr; Davis, L.; Vargas, H.M. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J. Pharmacol. Exp. Ther., 1996, 277(2), 728-738.
131. Lamirault, L.; Guillou, C.; Thal, C.; Simon, H. (-)-9- Dehydrogalanthaminium bromide, a new cholinesterase inhibitor, enhances place and object recognition memory in young and old rats. Neurobiol. Learn. Mem., 2003, 80(2), 113-122.
132. Firuzi, O.; Miri, R.; Tavakkoli, M.; Saso, L. Antioxidant therapy: current status and future prospects. Curr. Med. Chem., 2011, 18(25), 3871-3888.
133. Ribarova, F.; Stoimenova, A.; Popova, K. Antioxidant supplements in management of Parkinson's disease. Arch. Balk. Med. Union, 2009, 44(2), 142-145.
134. Rao, V.K.; Rao, A.J.; Reddy, S.S.; Raju, C.N.; Rao, P.V.; Ghosh, S.K. Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine. Eur. J. Med. Chem., 2010, 45(1), 203-209.
135. Liu, Q.; Xie, F.; Rolston, R.; Moreira, P.I.; Nunomura, A.; Zhu, X.; Smith, M.A.; Perry, G.Prevention and treatment of Alzheimer disease and aging: antioxidants. Mini Rev. Med. Chem., 2007, 7(2), 171-180.
136. Ding, Q.; Dimayuga, E.; Keller, N.J. Oxidative damage, protein synthesis, and protein degradation in Alzheimer's disease. Curr. Alzheimer Res., 2007, 4(1), 73-79.
137. Tsvetkova, D.; Zheleva-Dimitrova, D.; Obreshkova, D. Estimation of an antioxidant activity of new peptide esters of Galanthamine by applying ferric-reducing antioxidant powe (FRAP) method. Compt. Rend. Acad. Bulg. Sci., 2013, 66(3), 444-450.
138. Danchev, N.; Nikolova, I. Pharmacological treatment of cognitive impairements in Alzheimer's disease. Autonomic Autocoid Pharmacol., 2006, 26(1), 46-49.
139. Enz, A.; Amstutz, R.; Boddeke, H.; Gmelin, G.; Malonowski, J. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Progr. Brain Res., 1993, 98, 431-445.
140. Beher, D. Secretase modulation and it's promise for Alzheimer's disease: a rationale for drug discovery. Curr. Top. Med. Chem., 2008, 8(1), 34-37.
141. Gibson, G.E.; Huang, H.-M. Oxidative stress in Alzheimer's disease. Neurobiol. Aging, 2005, 26(5), 575-578.
142. Massaad, C.A. Neuronal and vascular oxidative stress in Alzheimer's Disease. Curr. Neuropharmacol., 2011, 9(4), 662-673.